Xi-ru Li, MD
Division of Breast Surgery, Department of General Surgery, General Hospital of Chinese, People's Liberation Army, Beijing, China
Dr. Xi-ru Li graduated from the Department of Clinical Medicine of the First Military Medical University in 1989 with a bachelor degree. He worked in the Department of General Surgery, Tang Du Hospital, Fourth Military Medical University, from 1989 to 2000, during which he received his master degree and was trained as attending physician and lecturer. He joined the Department of General Surgery of PLA General Hospital in September 2000. Currently he acts as the Deputy Executive Director of the Department of General Surgery and also is the chief of the Department of Breast Surgery in PLA General Hospital.
He acts as a consultant for China National Drug and Food Administration new drug evaluation, vice chairman of Military Breast and Endocrine Surgery Society, member of the Military General Surgery Society, member of Chinese Society of Clinical Oncology Breast Cancer Group, and member of Chinese Medical Doctor Association Breast Disease Group.
He has published 60 plus papers in domestic and international journals. He has obtained a national invention patent. He is the lead investigator of the following 4 key research projects. Meanwhile, he has been participating in many other studies supported by the National "973 Program", "863 Program", and Beijing Municipal Key Program.
His research and clinical interest includes sentinel lymph node biopsy, phase I and phase II breast reconstruction after surgery for breast cancer, mastectomy (SSM) with conservation of the nipple-areola complex, implants reconstruction, Mammotome minimally invasive breast surgery. Furthermore, he has standardized the multi-discipline breast-conserving treatment procedures, established a DNA bank for patients with breast cancer, and conducted pre-clinical and clinical research on pharamcogenomics-guided individualized treatment for breast cancer.
Terms of Appointment: May, 2012 - April, 2017; May, 2017 - April, 2022